This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Danya Sereda, MD; Victoria P. Werth, MD

Arch Dermatol. 2006;142:70-72.

Background  Dermatomyositis (DM) is an autoimmune disorder that occurs more often in women than men and causes highly symptomatic and inflammatory cutaneous and proximal muscle disease. Corticosteroids have been the treatment of choice for myositis in DM, and antimalarial agents for the skin disease of DM, with methotrexate sodium, azathioprine, mycophenolate mofetil, cyclosporine, and intravenous immunoglobulin used as steroid-sparing agents. Recently, reports supporting a role for anti–tumor necrosis factor (TNF-) therapy in the treatment of DM have emerged.

Observations  We describe 2 women who experienced an improvement in their DM-associated skin eruptions while taking antiestrogen medication. The first patient was taking tamoxifen, a selective estrogen receptor modulator that has been found to have anti–TNF- properties. The second was taking anastrozole, an aromatase inhibitor. When tamoxifen therapy was discontinued after 4 years of use in the first patient, her DM rash worsened and remained difficult to control with conventional immunosuppressant medication.

Conclusions  With the limited number of therapies available to manage DM skin eruptions, the discovery of novel agents effective in treating this disease is vital. Using antiestrogen medication in women with DM may result in a significant improvement in their rash, possibly via the inhibition of TNF- production by immune or other cells. Further investigation into the use of antiestrogen therapy in DM is merited to evaluate long-term risks and benefits.

Author Affiliations: Section of Dermatology, Université de Montréal (Dr Sereda); and Department of Dermatology, University of Pennsylvania Health System, and Philadelphia Veterans Affairs Hospital, Philadelphia (Dr Werth).

RELATED ARTICLES

Liver Enzyme Abnormalities in Patients With Atopic Dermatitis Treated With Mycophenolate Mofetil
Basil Hantash and David Fiorentino
Arch Dermatol. 2006;142(1):109-110.
EXTRACT | FULL TEXT  

An Unusual Presentation of Amyopathic Dermatomyositis Associated With Fatal Interstitial Lung Disease
Isaac M. Neuhaus and M. Kari Connolly
Arch Dermatol. 2006;142(1):113-114.
EXTRACT | FULL TEXT  

Mycophenolate Mofetil as an Effective Corticosteroid-Sparing Therapy for Recalcitrant Dermatomyositis
Johnathon C. Edge, J. David Outland, Jennifer R. Dempsey, and Jeffrey P. Callen
Arch Dermatol. 2006;142(1):65-69.
ABSTRACT | FULL TEXT  

The Era of Cooperation
Michael P. Heffernan
Arch Dermatol. 2006;142(1):93-95.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Successful Treatment of Dermatomyositis During Pregnancy With Intravenous Immunoglobulin Monotherapy
Williams et al.
Obstet Gynecol 2007;109:561-563.
ABSTRACT | FULL TEXT  

The Era of Cooperation
Heffernan
Arch Dermatol 2006;142:93-95.
FULL TEXT